Published online before print April 26, 2007

This Article Full Text (Rapid PDF) All Versions of this Article: jmoldx.2007.070017v1 9/3/394    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schrijver, I. Articles by Zehnder, J. L. Search for Related Content PubMed Articles by Schrijver, I. Articles by Zehnder, J. L.

Copyright © 2007 American Society for Investigative Pathology
Journal of Molecular Diagnostics, doi:10.2353/jmoldx.2007.070017

Accepted for publication February 23, 2007.

Regular Articles

Testing for Maternal Cell Contamination in Prenatal Samples. A Comprehensive Survey of Current Diagnostic Practices in 35 Molecular Diagnostic Laboratories

Iris Schrijver^*@, Sarah C. Cherny, and James L. Zehnder

From the Departments of Pathology and Pediatrics* and Pathology, Stanford University School of Medicine, Stanford, California

^@ To whom correspondence should be addressed. E-mail: ischrijver{at}stanfordmed.org.

	Abstract

The potential presence of maternal cell contamination (MCC) in chorionic villus or amniotic fluid samples poses a serious preanalytical risk for prenatal misdiagnosis. The aim of this study was to identify current diagnostic practices in the absence of comprehensive practice guidelines. Thirty-five clinical molecular laboratories that conduct prenatal testing agreed to participate in a clinical practice survey. The survey included questions about sample requirements, test indications, assay type, test performance and limitations, criteria and management of uninformative test results, reporting, and billing. Sixty percent of participating laboratories performed testing on direct and cultured amniotic fluid, whereas forty percent tested cultured cells only. Most also accepted chorionic villus samples. Although MCC testing of fetal samples is recommended in guidelines by the American College of Medical Genetics, only 60% of surveyed laboratories performed it without exception. Commercially available assays were used by 75% of participating laboratories, and at least five identity markers were evaluated at 87% of the laboratories. The reported lower limit of MCC detection ranged from 1 to 20% but was not determined in all laboratories. MCC testing was performed in the majority of molecular diagnostic laboratories, but guidelines for standardization are needed to ensure optimal and accurate prenatal patient care.